Avail Scientific, previously known as Mobile Lads, has signed a letter of intent (LOI) to acquire Florida based neurological testing and data management company Relai Neuro.
The biopharmaceutical company is focused on providing evidence-based diagnostic and data acquisition programs to help create therapies for addiction, and substance abuse.
It is also building a platform to both educate and equip healthcare professionals with the data to effectively use the therapeutic tools.
With the acquisition of Avail, Relai is enabled to double its sales force over the next three months as well as expand services into California, Texas, and Colorado.
Avail CEO Michael Paul said: “Relai Nero allows Avail to continue to accelerate our treatment applications, testing and supporting data collection as we strive to become a world leader in the clinically studied and supported use of psychedelic therapeutics for treatment of addiction & mental health issues.”
Relai Neuro is a data services and data management company that provides neurological testing and data management to rehab and mental health treatment centres in Florida.
The company offers products and methodology that enable direct measurement of progress in neural functions of patients under various treatments.
Relai has partnered with California-based medical equipment manufacturer Zeto to provide an FDA-certified EEG system.
The system is designed to deliver medical-grade EEG data, along with a highly scalable, versatile, durable, and cost-effective solution.
Relai Neuro CEO James Thompson said: “We are excited to work with Avail Scientific. The acquisition will allow us to bolster our offerings and our team.
“Additionally, the acquisition of Relai will allow us to achieve our goals of expansion in Florida, as well as expand quickly into California, Texas, and Colorado markets.”
